York Capital Management Global Advisors LLC Purchases Shares of 12,370 Genomic Health, Inc. (GHDX)

York Capital Management Global Advisors LLC purchased a new position in shares of Genomic Health, Inc. (NASDAQ:GHDX) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 12,370 shares of the medical research company’s stock, valued at approximately $423,000.

Several other hedge funds have also bought and sold shares of the business. Parametric Portfolio Associates LLC raised its stake in shares of Genomic Health by 5.8% during the second quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after acquiring an additional 441 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Genomic Health by 3.4% during the second quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock worth $516,000 after acquiring an additional 520 shares in the last quarter. Voya Investment Management LLC raised its stake in shares of Genomic Health by 18.5% during the second quarter. Voya Investment Management LLC now owns 8,622 shares of the medical research company’s stock worth $281,000 after acquiring an additional 1,344 shares in the last quarter. Meeder Asset Management Inc. raised its stake in shares of Genomic Health by 120.7% during the fourth quarter. Meeder Asset Management Inc. now owns 2,960 shares of the medical research company’s stock worth $101,000 after acquiring an additional 1,619 shares in the last quarter. Finally, New York State Common Retirement Fund raised its stake in shares of Genomic Health by 9.6% during the third quarter. New York State Common Retirement Fund now owns 22,900 shares of the medical research company’s stock worth $735,000 after acquiring an additional 2,000 shares in the last quarter. 91.18% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

GHDX has been the topic of several research reports. Canaccord Genuity reissued a “buy” rating and set a $39.00 price target on shares of Genomic Health in a research note on Wednesday, November 15th. JPMorgan Chase & Co. downgraded shares of Genomic Health from a “neutral” rating to an “underweight” rating and set a $25.00 price target on the stock. in a research note on Wednesday, December 13th. ValuEngine upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Friday, December 15th. BidaskClub upgraded shares of Genomic Health from a “sell” rating to a “hold” rating in a report on Tuesday, December 19th. Finally, William Blair cut shares of Genomic Health from an “outperform” rating to a “market perform” rating in a report on Wednesday, December 20th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating and one has assigned a buy rating to the company. Genomic Health currently has an average rating of “Hold” and a consensus target price of $32.67.

In other news, CEO Kimberly J. Popovits sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 14th. The shares were sold at an average price of $31.50, for a total value of $630,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $35.51, for a total transaction of $177,550.00. The disclosure for this sale can be found here. Insiders sold 84,280 shares of company stock worth $2,812,296 in the last 90 days. Company insiders own 46.20% of the company’s stock.

Shares of Genomic Health, Inc. (NASDAQ GHDX) traded up $0.13 during trading on Tuesday, hitting $33.39. 30,524 shares of the stock traded hands, compared to its average volume of 201,794. Genomic Health, Inc. has a 1 year low of $26.54 and a 1 year high of $37.50. The company has a market capitalization of $1,151.74, a PE ratio of -302.36 and a beta of 0.61.

Genomic Health (NASDAQ:GHDX) last issued its earnings results on Thursday, March 8th. The medical research company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Genomic Health had a negative return on equity of 0.85% and a negative net margin of 1.13%. The firm had revenue of $87.50 million during the quarter, compared to the consensus estimate of $88.96 million. During the same quarter in the prior year, the business posted $0.04 EPS. The firm’s revenue for the quarter was up 5.8% on a year-over-year basis. sell-side analysts predict that Genomic Health, Inc. will post 0.39 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “York Capital Management Global Advisors LLC Purchases Shares of 12,370 Genomic Health, Inc. (GHDX)” was first published by Markets Daily and is owned by of Markets Daily. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.themarketsdaily.com/2018/03/13/york-capital-management-global-advisors-llc-purchases-shares-of-12370-genomic-health-inc-ghdx.html.

Genomic Health Profile

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply